Sort
82,697 grants matching “vaccine development”
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus
$1,023,232Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2022 · AI
Scanning B. pseudomallei proteome for vaccine antigens
$1,023,198Philip Louis Felgner · University Of California-Irvine · U01 · FY2008 · AI
Studies of Chemokine-Receptor Interactions with Chemokines and alarmins
$1,023,149Joost J Oppenheim · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
Systems Biology Approaches to Viral Pathogenesis and Immunity
$1,023,092Michael G Katze · Oregon Health & Science University · U54 · FY2010 · AI
Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells
$1,022,964Michael-Christopher Keogh · Epicypher, Inc. · R44 · FY2023 · AI
XoLacta: An Adjuvant Therapy for treatment of Radiation Side effects during HER2-Positive Breast Cancer Treatment
$1,022,907Spencer Reid Marsh · Tiny Cargo Company, The · R44 · FY2025 · CA
Novel Immunoprophylaxes against Clostridium difficile Infection
$1,022,815Hanping Feng · University Of Maryland Baltimore · U19 · FY2018 · AI
Respiratory Syncytial Virus: Diagnostic and Vaccine Assays - VTEU
$1,022,794Larry Anderson · Emory University · N01 · FY2015 · AI
Tuberculosis Research Unit
$1,022,739W. Henry Boom · Case Western Reserve University · N01 · FY2012 · AI
Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells
$1,022,665Michael-Christopher Keogh · Epicypher, Inc. · R44 · FY2022 · AI
Collaborative Research: Ideas Lab: The Role of Extracellular RNA in Intercellular and Interkingdom Communication
$1,022,597Patricia Baldrich · Donald Danforth Plant Science Center · · FY2023 · BIO
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
$1,022,514Ashraf S. Ibrahim · Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center · R01 · FY2021 · AI
Clinical Trials Units for NIAID Networks (UM1)
$1,022,484Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2015 · AI
Antigen recognition and activation of HIV-specific B cell antigen receptors
$1,022,050S Munir Alam · Duke University · R01 · FY2025 · AI
Clinical and Biostatistics Core
$1,022,025Wilbur H. Chen · Univ Of Maryland, College Park · U19 · FY2021 · AI
Modulation of Human Cells by Virulent Francisella tularensis
$1,021,978Catharine Bosio · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Monoclonal Antibody to Combat Pseudomonas Aeruginosa
$1,021,806Joanna B. Goldberg · Emory University · R01 · FY2023 · AI
Epigenetic & Post-Translational Mechanisms of Macrophage Resistance to Mycobacterium tuberculosis During HIV Co-Infection
$1,021,774Thomas R Hawn · University Of Washington · R33 · FY2020 · AI
General Clinical Research Center
$1,021,752Richard D Krugman · University Of Colorado Denver · M01 · FY2008 · RR
Inhibition of hepatitis C by RNA-based therapeutics
$1,021,558Brian H. Johnston · Somagenics, Inc. · R44 · FY2007 · AI
Rational Design of Immunogens Targeting HIV-1 Quaternary Neutrlizing Epitopes
$1,021,515Xiangpeng Kong · New York University School Of Medicine · P01 · FY2016 · AI
Conserved Element DNA Vaccine
$1,021,081Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Monoclonal Antibody Therapy for West Nile Virus
$1,020,909Michael S. Diamond · Washington University · U01 · FY2007 · AI
PROTOZOAN PURINE PHOSPHORIBOSYLTRANSFERASES AS TARGETS TO TREAT MALARIA, AFRICAN TRYPANOSOMIASIS AND CHAGAS'S DISEASE
$1,020,767Thomas Meek · Texas A&M Agrilife Research · R01 · FY2020 · AI
Development of strategies to achieve immunoprotection against Cryptosporidiosis
$1,020,665Saul R Tzipori · University Of Maryland Baltimore · U19 · FY2017 · AI